# Can MOTS-c alleviate oxidative stress in aging and neurodevelopmental disorders?

Canonical source: https://retacompare.com/research/can-mots-c-alleviate-oxidative-stress-in-aging-and-neurodevelopmental-disorders

Peptide Longevity Q&A · 2026-02-18


    MOTS-c may alleviate autism-like behaviors and oxidative stress, suggesting its potential as a therapeutic candidate for autism spectrum disorder (ASD). This peptide acts independently of known neuroprotective factors, indicating a unique mechanism that could be relevant for longevity and neuroprotection.

 What the research shows

The study investigated the effects of MOTS-c in a valproic acid-induced autism model using Sprague-Dawley rats. Pregnant rats were administered valproic acid, leading to behavioral impairments in offspring. The offspring were treated with MOTS-c or saline, and various behavioral, histological, and biochemical analyses were conducted to assess the impact of MOTS-c on ASD symptoms and oxidative stress levels.

 Why it matters for longevity

Oxidative stress plays a significant role in the pathophysiology of various neurodevelopmental and age-related disorders. By potentially mitigating oxidative stress and improving behavioral outcomes in models of ASD, MOTS-c may offer insights into therapeutic strategies that could extend healthspan and enhance neuroprotection in aging populations. Understanding its mechanisms may provide valuable information for developing interventions that target age-related cognitive decline.

 Key findings at a glance

MOTS-c was tested in a rat model of autism induced by valproic acid.

Treatment with MOTS-c reversed several autism-like behaviors, including impaired sociability.

The peptide did not significantly change plasma levels of tetrahydrobiopterin (BH4) or brain-derived neurotrophic factor (BDNF).

MOTS-c exhibited neuroprotective and antioxidant effects independent of BH4 and BDNF.

Some behaviors, such as anxiety, were not significantly improved by MOTS-c treatment.

 How MOTS-c works (background)

MOTS-c is a mitochondrial-derived peptide that influences cellular metabolism and energy homeostasis. It operates through the activation of AMP-activated protein kinase (AMPK), a critical regulator of energy balance. By mimicking the effects of exercise, MOTS-c may enhance mitochondrial function and reduce oxidative stress, which is particularly relevant in neurodevelopmental disorders like ASD. This mechanism highlights the potential of MOTS-c in promoting neuroprotection and longevity.

 Safety, caveats, and what we don't yet know

While the study suggests that MOTS-c has beneficial effects in a preclinical model, it is important to note that the research is still in its early stages. The peptide's safety profile, long-term effects, and efficacy in human populations remain unclear. Additionally, the specific mechanisms through which MOTS-c exerts its effects require further investigation to understand its full potential in treating neurodevelopmental disorders and its implications for aging.

 Bottom line

MOTS-c shows promise in alleviating oxidative stress and autism-like behaviors in a rat model, indicating its potential therapeutic role in neurodevelopmental disorders and implications for longevity.

 Related questions

 Does MOTS-c improve mitochondrial function in aging cells?

Research indicates that MOTS-c activates AMPK, which may enhance mitochondrial function. This activation is crucial for energy metabolism and could have implications for aging cells.

 Can MOTS-c reduce inflammation in neurodegenerative diseases?

While specific studies on MOTS-c and inflammation are limited, its antioxidant properties suggest potential for reducing oxidative stress, which is often linked to neurodegenerative diseases.

 What are the potential applications of MOTS-c in aging research?

MOTS-c may have applications in aging research due to its neuroprotective effects and ability to alleviate oxidative stress, making it a candidate for further exploration in age-related cognitive decline.

 Source: PubMed · Mol Neurobiol · published 2026-02-18.

## Sources

- PubMed · Mol Neurobiol: https://pubmed.ncbi.nlm.nih.gov/41706383/